GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Cash Flow from Financing

Implantica AG (OSTO:IMP A SDB) Cash Flow from Financing : kr0.00 Mil (TTM As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in . 20, Implantica AG paid kr0.00 Mil more to buy back shares than it received from issuing new shares. It received kr0.00 Mil from issuing more debt. It paid kr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received kr0.00 Mil from paying cash dividends to shareholders. It received kr0.00 Mil on other financial activities. In all, Implantica AG spent kr0.00 Mil on financial activities for the six months ended in . 20.


Implantica AG Cash Flow from Financing Historical Data

The historical data trend for Implantica AG's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Cash Flow from Financing Chart

Implantica AG Annual Data
Trend
Cash Flow from Financing

Implantica AG Semi-Annual Data
Cash Flow from Financing

Implantica AG Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Implantica AG's Cash from Financing for the fiscal year that ended in . 20 is calculated as:

Implantica AG's Cash from Financing for the quarter that ended in . 20 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in . 20 was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Implantica AG  (OSTO:IMP A SDB) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Implantica AG's issuance of stock for the six months ended in . 20 was kr0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Implantica AG's repurchase of stock for the six months ended in . 20 was kr0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Implantica AG's net issuance of debt for the six months ended in . 20 was kr0.00 Mil. Implantica AG received kr0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Implantica AG's net issuance of preferred for the six months ended in . 20 was kr0.00 Mil. Implantica AG paid kr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Implantica AG's cash flow for dividends for the six months ended in . 20 was kr0.00 Mil. Implantica AG received kr0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Implantica AG's other financing for the six months ended in . 20 was kr0.00 Mil. Implantica AG received kr0.00 Mil on other financial activities.


Implantica AG Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Implantica AG's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Implantica AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines